Nonpharmacological Therapies for Interstitial Lung Disease
نویسندگان
چکیده
منابع مشابه
Nonpharmacological Therapies for Atrial Fibrillation
1Division of Cardiology (Heart Rhythm Service), Kingston General Hospital, Queen’s University, Kingston, ON, Canada K7L 2V7 2Cardiac Arrhythmia and Electrophysiology Unit, Department of Cardiology, Hospital Virgen de la Salud, 45004 Toledo, Spain 3Department of Cardiovascular Medicine, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium 4Southlake Heart Rhythm Program, Division of Cardiology, Southlake...
متن کاملLung transplantation for interstitial lung disease.
Lung transplantation remains the only therapeutic option shown to improve survival for many end-stage interstitial lung diseases. Although idiopathic pulmonary fibrosis is the most common indication, transplantation has been performed for many other diseases. This article reviews the current indications and outcomes for the procedure and problems encountered in lung transplantation for intersti...
متن کاملNonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy.
INTRODUCTION Nonpharmacological therapies (NPTs) can improve the quality of life (QoL) of people with Alzheimer's disease (AD) and their carers. The objective of this study was to evaluate the best evidence on the effects of NPTs in AD and related disorders (ADRD) by performing a systematic review and meta-analysis of the entire field. METHODS Existing reviews and major electronic databases w...
متن کاملInherited interstitial lung disease.
This article focuses on recent advances in the identification of genes and genetic polymorphisms that have been implicated in the development of human interstitial lung diseases. It focuses on the inherited mendelian diseases in which pulmonary fibrosis is part of the clinical phenotype and the genetics of familial idiopathic pulmonary fibrosis and other rare inherited interstitial lung disease...
متن کامل[Interstitial lung disease].
This concise article summarizes recent advances in the field of interstitial lung disease (ILD) with particular focus on clinically relevant findings. As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for the treatment of mild to moderate IPF. In contrast, the FDA refused to approve pirfenidone for the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Pulmonology Reports
سال: 2018
ISSN: 2199-2428
DOI: 10.1007/s13665-018-0211-6